Role of Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma: Analysis from a Propensity-Matched Retrospective Cohort
Brazilian Journal of Oncology · 26.06.2026 · 22 (CP)
DOI: 10.1055/s-0046-1825501 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brazilian Journal of Oncology, erschienen am 26.06.2026. Verfasst von Letícia Kimie Murazawa und 11 weiteren Autor:innen.
Abstract (Originalsprache)
All articles of this category (opens in new window) Address for correspondence Letícia Kimie Murazawa (leticiamurazawa@gmail.com)
Introduction
The benefit of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma has been challenged by prospective trials including patients with clear cell disease, where systemic therapy alone is standard. However, non-clear cell renal cell carcinoma represents a biologically and clinically distinct group, often excluded from these trials and lacking high-level evidence to guide treatment. Whether cytoreductive nephrectomy improves survival in this population remains unknown.
Objective
To evaluate the impact of cytoreductive nephrectomy on overall survival (OS) in patients with metastatic non-clear cell renal cell carcinoma (nccRCC) treated at a large academic cancer center in Brazil.
Methods
We conducted a retrospective analysis of patients with metastatic nccRCC treated between September 2009 and January 2024. Baseline data included ECOG performance status, IMDC risk classification, histologic subtype (per 2022 WHO criteria), and number of metastatic sites. Cytoreductive nephrectomy was defined as nephrectomy performed in the setting of metastatic disease. OS was calculated from metastatic diagnosis to death or last follow-up. Survival curves were generated using the Kaplan-Meier method and compared via the log-rank test. Propensity score matching was applied to reduce selection bias.
Results
Among 2,867 patients with kidney cancer, 620 (21.6%) had nccRCC, of whom 146 (23.5%) had metastatic disease. Twenty-eight patients (19.2%) underwent cytoreductive nephrectomy. After matching, no overall OS benefit was observed (median OS 18.9 vs. 15.0 months; HR 0.81, 95% CI 0.45–1.45). Subgroup analysis showed a significant OS advantage in poor-risk IMDC patients (median OS 18.9 vs. 4.5 months; HR 0.29, 95% CI 0.08–0.98). No benefit was seen in patients with papillary histology (median OS 21.9 vs. 19.6 months; HR 0.90, 95% CI 0.39–2.06) or intermediate IMDC risk (median OS 12.2 vs. 19.6 months; HR 1.08, 95% CI 0.49–2.43).
Conclusion
Although cytoreductive nephrectomy did not improve survival in the overall metastatic nccRCC cohort, it was associated with better OS in patients with poor IMDC risk, suggesting potential benefit in selected cases. Publication History Article published online: 26 June 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil Bibliographical Record Letícia Kimie Murazawa, Rogério Almeida Moreno Santos, Matheus Henrique Juliani Arneiro, Gabriel Berlingieri Polho, Luísa Canesin Dourado Figueiredo Costa, Vinícius Cruz Parrela, Matheus de Oliveira Andrade, Gustavo Luis Contado Alves, Douglas Tozzo Machado Ferreira, Vitor Hugo Felix, Nathália de Souza Del Rey Crusoé, José Mauricio Segundo Correia Mota. Role of Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma: Analysis from a Propensity-Matched Retrospective Cohort. Brazilian Journal of Oncology 2026; 22. DOI: 10.1055/s-0046-1825501
Zitieren
APA
Murazawa, L. K., Santos, R. A. M., Arneiro, M. H. J., Polho, G. B., Costa, L. C. D. F., Parrela, V. C., Andrade, M. D. O., Alves, G. L. C., Ferreira, D. T. M., Felix, V. H., Crusoé, N. D. S. D. R., & Mota, J. M. S. C. (2026). Role of Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma: Analysis from a Propensity-Matched Retrospective Cohort. Brazilian Journal of Oncology, 22(CP). https://doi.org/10.1055/s-0046-1825501
Vancouver
Murazawa LK, Santos RAM, Arneiro MHJ, Polho GB, Costa LCDF, Parrela VC, et al. Role of Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma: Analysis from a Propensity-Matched Retrospective Cohort. Brazilian Journal of Oncology. 2026;22(CP). doi:10.1055/s-0046-1825501
BibTeX
@article{Murazawa2026,
author = {Murazawa, Letícia Kimie and Santos, Rogério Almeida Moreno and Arneiro, Matheus Henrique Juliani and Polho, Gabriel Berlingieri and Costa, Luísa Canesin Dourado Figueiredo and Parrela, Vinícius Cruz and Andrade, Matheus de Oliveira and Alves, Gustavo Luis Contado and Ferreira, Douglas Tozzo Machado and Felix, Vitor Hugo and Crusoé, Nathália de Souza Del Rey and Mota, José Mauricio Segundo Correia},
title = {Role of Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma: Analysis from a Propensity-Matched Retrospective Cohort},
journal = {Brazilian Journal of Oncology},
year = {2026},
volume = {22},
number = {CP},
doi = {10.1055/s-0046-1825501}
}
EUVIMED